BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 11423629)

  • 1. KLF4 suppresses transformation of pre-B cells by ABL oncogenes.
    Kharas MG; Yusuf I; Scarfone VM; Yang VW; Segre JA; Huettner CS; Fruman DA
    Blood; 2007 Jan; 109(2):747-55. PubMed ID: 16954505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
    Gorre ME; Mohammed M; Ellwood K; Hsu N; Paquette R; Rao PN; Sawyers CL
    Science; 2001 Aug; 293(5531):876-80. PubMed ID: 11423618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roots of clinical resistance to STI-571 cancer therapy.
    Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
    [No Abstract]   [Full Text] [Related]  

  • 4. Roots of clinical resistance to STI-571 cancer therapy.
    Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
    [No Abstract]   [Full Text] [Related]  

  • 5. Quick success for cancer kinase treatment.
    Nat Med; 2001 Jun; 7(6):637. PubMed ID: 11385473
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer research. Why some leukemia cells resist STI-571.
    Marx J
    Science; 2001 Jun; 292(5525):2231-3. PubMed ID: 11423629
    [No Abstract]   [Full Text] [Related]  

  • 7. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Druker BJ; Lydon NB
    J Clin Invest; 2000 Jan; 105(1):3-7. PubMed ID: 10619854
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
    Shah NP; Sawyers CL
    Curr Opin Investig Drugs; 2001 Mar; 2(3):422-3. PubMed ID: 11575716
    [No Abstract]   [Full Text] [Related]  

  • 9. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to imatinib mesylate in chronic myeloid leukaemia.
    Melo JV; Chuah C
    Cancer Lett; 2007 May; 249(2):121-32. PubMed ID: 16949736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
    Druker BJ
    Oncogene; 2002 Dec; 21(56):8541-6. PubMed ID: 12476300
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.